網膜静脈閉塞症（RVO）の世界市場-2024-2032

世界の網膜静脈閉塞症（RVO）市場は、2023年に8億5,637万米ドルに達し、そして2032年には19億1,381万米ドルに達し、予測期間2024-2032年にCAGR 9.4％で成長すると予測されています。

網膜静脈閉塞症とは、光の像を神経信号に変換して脳に送る目の主要部分である網膜から血液を送り出す細い静脈が閉塞することです。網膜静脈閉塞症は主に動脈硬化によって引き起こされ、硬化した動脈が血栓を形成します。網膜静脈閉塞症（RVO）は2番目に多い網膜血管疾患であり、高齢の患者によく見られる視力低下です。RVOには網膜静脈分枝閉塞症（BRVO）と網膜中心静脈閉塞症（CRVO）の2種類があります。網膜中心静脈閉塞症は、視神経の篩骨（しこつ）の後方にある主網膜静脈の閉塞であり、一般的に血栓症によって引き起こされます。

市場力学：

促進要因と抑制要因

網膜静脈閉塞症の有病率の上昇

網膜静脈閉塞症（RVO）の世界の疾病負担は、人口の高齢化と心血管疾患や肥満などの危険因子の有病率の増加により増加しています。年齢は網膜静脈閉塞症の重大な危険因子であり、2022年2月にJournal of Opthalmology Retina誌に発表されたレトロスペクティブ研究によると、網膜静脈閉塞症は65～85歳の高齢者に高率にみられます。人口のサブタイプでは、65歳から85歳がRVO症例の70.3％を占め、次いで45歳から65歳が24.3％、25歳から45歳が2.7％、85歳以上が2.2％、25歳以下が0.5％でした。

これは、年齢とともに網膜静脈閉塞症（RVO）の発症率が上昇することを意味しています。世界的に高齢化が進んでおり、特にアジア太平洋地域では、網膜静脈閉塞症（RVO）の症例数が予測期間中に急増することが予想され、先進的な治療に対する需要が生まれると同時に、既存の治療法の普及率も高まることが予想されます。

治療費の高さは網膜静脈閉塞症（RVO）市場成長の大きな障壁となりうる。

抗VEGF薬は網膜静脈閉塞症（RVO）患者の治療のゴールドスタンダードと考えられています。しかし、これらの薬剤は、患者の視力を改善し、生活の質を向上させるために複数回の投与が必要であるため、しばしば高価です。コストの壁があるため、患者が適切な保険に加入していない特定の低・中所得国では、採用率が低い可能性があります。

例えば、網膜静脈閉塞症の発症率は、世界の高齢者人口の大半が居住するアジア太平洋地域で高いです。アジア太平洋諸国の大半は中所得国で、国民は健康保険に加入していないです。例えば、フィリピンでは、エイレア（アフリベルセプト）1バイアルにかかる費用は最大6万米ドル（1,000米国ドル）です。これはフィリピンの患者にとって大きな経済的負担となります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 網膜静脈閉塞症の罹患率の上昇
    • 新薬開発の進展
  • 抑制要因
    • 治療費が高い
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• パイプライン分析
• 疫学
• 特許分析
• 規制分析

第6章 タイプ別

• 網膜中心静脈閉塞症（CRVO）
  • 網膜静脈分枝閉塞症（BRVO）

第7章 治療別

• 抗血管内皮増殖因子（抗VEGF）薬
  • ラニビズマブ
  • ファリシマブ
  • アフリベルセプト
• コルチコステロイド
  • デキサメタゾン
  • トリアムシノロンアセトニド
• レーザー治療
• 手術

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第10章 企業プロファイル

• Bayer AG
  • 会社概要
  • タイプポートフォリオと概要
  • 財務概要
  • 主な発展
• Regeneron Pharmaceuticals Inc.
• F. Hoffmann-La Roche Ltd
• Teva Pharmaceutical Industries Ltd.
• AbbVie.
• Sunshine Guojian Pharmaceutical（Shanghai）Co.,Ltd.
• KODIAK SCIENCES INC.
• TAIWAN LIPOSOME CO., LTD.

第11章 付録

The global retinal vein occlusion (RVO) market reached US$ 856.37 million in 2023 and is expected to reach US$ 1,913.81 million by 2032, growing at a CAGR of 9.4% during the forecast period 2024-2032.

Retinal vein occlusion is the blockage of small veins that transport blood away from the retina a major part of the eye which converts light images into nerve signals and sends them to the brain. Retinal vein occlusion is primarily caused by atherosclerosis, where hardened arteries form blood clots. Retinal vein occlusion (RVO) is the second most common retinal vascular disease and is a common loss of vision in older patients. There are two types of RVO: branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Central retinal vein occlusion is an occlusion of the main retinal vein posterior to the lamina cribrosa of the optic nerve and is typically caused by thrombosis.

Market Dynamics: Drivers & Restraints

Rising prevalence of retinal vein occlusion

The global disease burden of retinal vein occlusion (RVO) is rising due to the aging population and increased prevalence of risk factors such as cardiovascular diseases and obesity. Age is a serious risk factor for retinal vein occlusion, a retrospective study published in the Journal of Opthalmology Retina in February 2022 has stated that retinal vein occlusion is highly prevalent among people aged 65 to 85 years. Among the population subtypes, 65 to 85 years old composed 70.3% of RVO cases followed by the 45 to 65 age group accounting for 24.3% of cases, the 25 to 45 age group accounting for 2.7% of cases, above 85 age group representing 2.2% of cases, and below 25 age group representing 0.5% of total cases.

This signifies that with age, the incidence of retinal vein occlusion (RVO) rises. As the global population is aging, especially in the Asia-Pacific region, the number of retinal vein occlusion (RVO) cases is expected to surge in the forecasted period, creating a demand for advanced therapies, and also increasing the adoption rate of existing treatments.

The high cost of treatment can be a significant barrier to retinal vein occlusion (RVO) market growth.

Anti-VEGF drugs are considered the gold standard for the treatment of patients with retinal vein occlusion (RVO). However, these drugs are often expensive, as multiple administrations are required to improve the patient's vision and improve their quality of life. Due to the cost barrier, the adoption rates may be low in certain low-to-middle-income countries where the patients don't have proper insurance coverage.

For instance, the incidence of retinal vein occlusion is high in the Asia-Pacific region, where the majority of the global elderly population resides. The majority of the Asia-Pacific countries are middle-income countries and the population lacks health insurance. For instance, in the Philippines, the cost of 1 vial of Eylea (Aflibercept) can cost up to ₱ 60,000.00 (US$ 1,000). This can be a significant economic burden to patients in the country.

Segment Analysis

The global Retinal vein occlusion (RVO) market is segmented based on type, treatment, and region.

Anti-vascular endothelial growth factor (Anti-VEGF) drugs are dominating the treatment type segment with the highest market share.

Vascular endothelial growth factor (VEGF) is a protein produced in the body, that promotes vasculature growth. This growth in blood vessels plays a crucial role in physiological processes such as embryogenesis, skeletal growth, and reproductive functions. However, VEGF is also involved in the pathogenesis of certain diseases such as tumor growth, neovascularization of the eye, etc. In retinal vein occlusion (RVO), vascular endothelial growth factor plays a crucial role in increasing vascular permeability, inflammation, and abnormal blood vessel growth. This abnormal growth may cause ischemia in the vein that drains the blood from the retina.

Anti-VEGF drugs inhibit the vascular endothelial growth factor thereby reducing macular edema, restoring the blood flow, and improving vision. The currently approved anti-vascular endothelial growth factor (Anti-VEGF) drugs are ranibizumab, aflibercept, and faricimab. In addition to these drugs, although not approved, bevacizumab is widely used off-label. Several clinical studies have reported the therapeutic efficiency of anti-VEGF drugs in retinal vein occlusion (RVO) and have labeled them as gold-standard therapies.

For instance, a meta-analysis study published in Springer Nature Journals in March 2024, has stated that anti-VEGF drugs have evolved as a standard of care option in retinal vein occlusion treatment as they have been proven to inhibit vascular leakage and effectively improve and maintain vision.

Geographical Analysis

North America is expected to hold a significant share of the Retinal vein occlusion (RVO) market.

North America is estimated to hold the highest market share throughout the forecast period, owing to factors like highly regulated and well-developed healthcare infrastructure. The growing collective efforts of key players to improve their product portfolios and ensure high-quality standards are expected to boost the demand for RVO treatment across this region. The increasing prevalence of retinal vein occlusion (RVO) is estimated to be a major factor influencing market growth in the region.

For instance, in January 2024, Genentech, Inc. a subsidiary of F. Hoffmann-La Roche Ltd stated that retinal vein occlusion (RVO) is the second most common cause of blindness in the U.S., and affects more than 1 million population with 60 years and older accounting for the majority of the cases.

With the rising aging population and rising prevalence of retinal vein occlusion (RVO) in the U.S., there are continued efforts by market leaders to launch novel therapies in the North America region.

For instance, in October 2023, the U.S. Food and Drug Administration (FDA) approved Vabysmo for the treatment of retinal vein occlusion. Vabysmo (faricimab-svoa) is the novel anti-vascular endothelial growth factor developed by F. Hoffmann-La Roche Ltd.

All these factors stated above are significant contributors to the region's dominance in the global retinal vein occlusion (RVO) market.

Competitive Landscape

The major global players in the Retinal vein occlusion (RVO) market are Bayer AG, Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., and AbbVie. among others.

Emerging Players

The emerging players in the Retinal vein occlusion (RVO) market include Sunshine Guojian Pharmaceutical (Shanghai)Co.,Ltd., KODIAK SCIENCES INC., and TAIWAN LIPOSOME CO., LTD. among others.

Key Developments

• In December 2024, Regeneron Pharmaceuticals, Inc. published the phase 3 clinical trial results for EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO), including those with central, branch and hemiretinal vein occlusions. The study met its primary end-point of improving vision in the subject population.
• In July 2024, F. Hoffmann-La Roche Ltd announced that the European Commission (EC) approved Vabysmo (Faricimab) for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO).
• Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and Type pipelines, and forecasts upcoming pharmaceutical advancements.
• Type Performance & Market Positioning: Analyzes Type performance, market positioning, and growth potential to optimize strategies.
• Real-world Evidence: Integrates patient feedback and data into drug-type development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance Type safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Retinal vein occlusion (RVO) market report would provide approximately 48 tables, 40 figures, and 170 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising prevalence of retinal vein occlusion
    • 4.1.1.2. Rising development of novel drugs
  • 4.1.2. Restraints
    • 4.1.2.1. High cost of treatment
  • 4.1.3. Opportunities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Pipeline Analysis
• 5.5. Epidemiology
• 5.6. Patent Analysis
• 5.7. Regulatory Analysis

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Central Retinal Vein Occlusion (CRVO)*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Branch Retinal Vein Occlusion (BRVO)

7. By Treatment

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 7.1.2. Market Attractiveness Index, By Treatment
• 7.2. Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Ranibizumab
  • 7.2.4. Faricimab
  • 7.2.5. Aflibercept
• 7.3. Corticosteroids
  • 7.3.1. Dexamethasone
  • 7.3.2. Triamcinolone Acetonide
• 7.4. Laser Therapy
• 7.5. Surgery

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Spain
    • 8.3.5.5. Italy
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. South Korea
    • 8.5.5.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

• 10.1. Bayer AG*
  • 10.1.1. Company Overview
  • 10.1.2. Type Portfolio and Description
  • 10.1.3. Financial Overview
  • 10.1.4. Key Developments
• 10.2. Regeneron Pharmaceuticals Inc.
• 10.3. F. Hoffmann-La Roche Ltd
• 10.4. Teva Pharmaceutical Industries Ltd.
• 10.5. AbbVie.
• 10.6. Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.
• 10.7. KODIAK SCIENCES INC.
• 10.8. TAIWAN LIPOSOME CO., LTD.

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us